Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roquefort Investments PLC ( (GB:ROQ) ) has provided an update.
Roquefort Therapeutics PLC has announced a transformative acquisition of Coiled Therapeutics, Inc., a clinical stage oncology company, through a reverse takeover valued at £30 million in shares. This strategic move aims to pivot Roquefort into a clinical stage biotech company, enhancing its market position with advanced clinical assets like AO-252, a promising cancer treatment currently in Phase I trials. The transaction includes a significant funding commitment from A2A Pharmaceuticals, which will support the company’s growth and development. The acquisition is expected to create substantial value for shareholders and establish a strategic partnership with A2A Pharmaceuticals, leveraging their SCULPT™ platform for future opportunities.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on transforming from pre-clinical to clinical stage assets. The company is involved in drug development, leveraging machine learning capabilities to enhance clinical outcomes.
Average Trading Volume: 1,485,502
Technical Sentiment Signal: Sell
Current Market Cap: £2.6M
For an in-depth examination of ROQ stock, go to TipRanks’ Overview page.